Vtv Therapeutics Inc. current report, 29 July 2015

Business Context and Reporting Period

This Form 8-K, dated July 29, 2015, reports the consummation of vTv Therapeutics Inc.'s initial public offering (IPO) and a series of reorganization transactions. The Company, incorporated in Delaware, completed the offering of its Class A common stock and restructured its corporate entity to separate economic interests from voting control.

Key Financial Metrics and Capital Structure

  • Offering Size: 7,812,500 shares of Class A Common Stock sold to underwriters.
  • Offering Price: $15.00 per share to the public.
  • Underwriting Discount: $1.05 per share (Purchase price to underwriters was $13.95).
  • Over-Allotment Option: Underwriters granted an option to purchase up to 1,171,875 additional shares.
  • Ownership Structure Post-Offering:
    • Company holds 23.8% of economic interests in vTv Therapeutics LLC.
    • Holdings (affiliate of MacAndrews & Forbes) holds 76.2% of economic interests.
    • Affiliates of MacAndrews beneficially own 81.3% of total voting power.
  • Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.

Material Changes and Transactions

The Company executed a complex reorganization to facilitate the IPO, resulting in the following material changes:

  • Corporate Restructuring: Assets and operations were contributed from vTvx I and vTvx II to Holdings, and subsequently to vTv Therapeutics LLC. The Company now holds only a direct interest in vTv Therapeutics LLC.
  • Stock Class Creation:
    • Class A Common Stock: Represents economic interests with one vote per share.
    • Class B Common Stock: Issued to Holdings; represents no economic interests but carries one vote per share.
  • Unregistered Sales: 25,000,000 shares of Class B Common Stock were issued to Holdings in exchange for contributed assets under Section 4(a)(2) exemption.
  • Charter Amendments: The Certificate of Incorporation and By-Laws were amended and restated to reflect the new capital structure.

Agreements, Risks, and Contingencies

The filing details several material definitive agreements entered into on July 29, 2015:

  • Underwriting Agreement: Piper Jaffray & Co. and Stifel, Nicolaus & Company, Inc. acted as representatives. The Company agreed to indemnify underwriters against certain liabilities.
  • Exchange Agreement: Holdings may exchange Class B Common Stock and LLC Units for Class A Common Stock (1-for-1) or cash at the Company's option.
  • Tax Receivable Agreement (TRA): The Company must pay Holdings 85% of cash tax savings realized from the exchange of Class B stock or other tax benefits related to the TRA.
  • Investor Rights Agreement: Grants Holdings demand, shelf, and piggyback registration rights. It also provides Holdings with the right to designate a majority of the Board of Directors as long as it owns more than 50% of the outstanding common stock.
  • Equity Incentive Plan: Adoption of the 2015 Omnibus Equity Incentive Plan for executive officers and directors.

Investor Verification Checklist

  • Verify the final number of shares issued if the underwriters' over-allotment option was exercised.
  • Review the full text of the Tax Receivable Agreement to understand the potential cash outflow obligations to Holdings.
  • Confirm the current composition of the Board of Directors and the extent of MacAndrews & Forbes' control rights.
  • Examine the Registration Statement (Form S-1, File No. 333-204951) for detailed financial statements and risk factors not included in this 8-K.
  • Monitor the liquidity of Class B Common Stock, as it is non-transferable except in connection with an exchange of corresponding LLC Units.